Novartis | NVS - Debitur Perdagangan





Debitur Perdagangan Perubahan Tanggal
AbbVie USD 12.59B 180M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Bausch Health Companies USD 2.19B 160M 2026-03
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Canopy Growth CAD 36.29M 104.13M 2026-03
Corcept Therapeutics USD 39.07M 20.71M 2026-03
Drreddys Laboratories INR 123.17B 121.76B 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Glaxosmithkline GBP 10.49B 40.6M 2026-03
J&J USD 22.54B 1.21B 2026-03
Merck USD 11.78B 345M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pacira USD 125.64M 1.57M 2026-03
Perrigo USD 697.1M 84.3M 2026-03
Pfizer USD 16.17B 332M 2026-03
Phibro Animal Health USD 215.87M 2.02M 2025-12
Prestige Brands USD 191.92M 1.46M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sanofi EUR 482M 85M 2026-03
Sanofi EUR 482M 85M 2026-03
Supernus Pharmaceuticals USD 182.18M 5.62M 2026-03
Zoetis USD 1.51B 84M 2026-03